help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chun, T.-Y.
Right arrow Articles by Pratt, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chun, T.-Y.
Right arrow Articles by Pratt, J. H.
Endocrinology Vol. 144, No. 5 1712-1717
Copyright © 2003 by The Endocrine Society

Aldosterone Inhibits Inducible Nitric Oxide Synthase in Neonatal Rat Cardiomyocytes

Tae-Yon Chun, Laura J. Bloem and J. Howard Pratt

Department of Medicine (T.-Y.C., J.H.P.) and the Veterans Affairs Medical Center (J.H.P.), Indiana University Medical School, Indianapolis, Indiana 46202; and Lilly Research Laboratories (L.J.B.), Eli Lilly and Co., Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Tae-Yon Chun, Ph.D., Department of Medicine, 541 Clinical Drive, Room 458, Indianapolis, Indiana 46202. E-mail: tchun{at}iupui.edu.

In studies of animals, increases in aldosterone are associated with myocardial necrosis and fibrosis, and treatment with spironolactone, an antagonist of aldosterone, improved clinical outcomes in patients with heart failure. In the present study, we explored nitric oxide (NO), a signaling molecule involved in cardiac function, as a potential mediator of aldosterone’s effects on the heart. Levels of both inducible NO synthase (iNOS) and NO from isolated rat neonatal cardiomyocytes pretreated with IL-1 were found to be decreased with exposure to aldosterone or dexamethasone in a dose-dependent manner. Spironolactone increased iNOS expression and prevented inhibition by aldosterone, consistent with a mineralocorticoid receptor-mediated mechanism for iNOS down-regulation. Aldosterone had no effect on iNOS mRNA levels, indicating a posttranscriptional mechanism for the inhibition of iNOS. Neutralization of TGF-ß1 using a specific antibody reversed aldosterone-dependent iNOS and NO down-regulation. In summary, aldosterone inhibited IL-1- induced iNOS expression posttranscriptionally by a TGF-ß1-dependent mechanism. The decrease in NO synthesis could have relevance to known cardiac effects of aldosterone.




This article has been cited by other articles:


Home page
HypertensionHome page
J. Diez
Effects of Aldosterone on the Heart: Beyond Systemic Hemodynamics?
Hypertension, September 1, 2008; 52(3): 462 - 464.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T.-Y. Chun, P. N. Chander, J.-W. Kim, J. H. Pratt, and C. T. Stier Jr.
Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats
Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E305 - E312.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
D. Duboc, C. Meune, B. Pierre, K. Wahbi, B. Eymard, A. Toutain, C. Berard, G. Vaksmann, and H.-M. Becane
Perindopril preserves left ventricular function in X-linked Duchenne muscular dystrophy
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E20 - E24.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Fejes-Toth and A. Naray-Fejes-Toth
Early Aldosterone-Regulated Genes in Cardiomyocytes: Clues to Cardiac Remodeling?
Endocrinology, April 1, 2007; 148(4): 1502 - 1510.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. J. Fuller and M. J. Young
Mechanisms of Mineralocorticoid Action
Hypertension, December 1, 2005; 46(6): 1227 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. N. Helms, L. Yu, B. Malik, D. J. Kleinhenz, C. M. Hart, and D. C. Eaton
Role of SGK1 in nitric oxide inhibition of ENaC in Na+-transporting epithelia
Am J Physiol Cell Physiol, September 1, 2005; 289(3): C717 - C726.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
F. K Shieh, E. Kotlyar, and F. Sam
Aldosterone and cardiovascular remodelling: focus on myocardial failure
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society